Statin-Induced Rhabdomyolysis.

Area of Science:

• Medicine
• Pharmacology
• Nephrology

Background:

• Rhabdomyolysis is a clinical syndrome resulting from muscle fiber breakdown, leading to the release of intracellular contents like myoglobin into circulation.
• Dyslipidemia is a common condition managed with statin medications, which are widely prescribed for cardiovascular disease prevention.
• The spectrum of rhabdomyolysis ranges from subclinical muscle enzyme elevations to severe, life-threatening conditions including acute kidney injury.

Observation:

• This report details a case of rhabdomyolysis precipitated by statin therapy.
• The patient presented with symptoms indicative of muscle damage and subsequent renal impairment.

Findings:

• Statin-induced rhabdomyolysis can manifest with significant muscle enzyme elevation.
• Acute renal failure is a potential severe complication of statin-induced rhabdomyolysis.

Implications:

• This case underscores the importance of monitoring for rhabdomyolysis in patients initiating or using statin therapy.
• Awareness of this adverse drug reaction is crucial for clinicians to prevent severe outcomes like renal failure.
• Further research into the mechanisms and risk factors for statin-induced rhabdomyolysis may improve patient safety.